Literature DB >> 33727227

Single-Cell RNA Sequencing Reveals the Cellular Origin and Evolution of Breast Cancer in BRCA1 Mutation Carriers.

Li Hu1, Liming Su1, Hainan Cheng2, Chunling Mo2, Tao Ouyang1, Jinfeng Li1, Tianfeng Wang1, Zhaoqing Fan1, Tie Fan1, Benyao Lin1, Jianguang Zhang3, Yuntao Xie4.   

Abstract

The cell of origin and the development of breast cancer are not fully elucidated in BRCA1 mutation carriers, especially for estrogen receptor (ER)-positive breast cancers. Here, we performed single-cell RNA sequencing (RNA-seq) on 82,122 cells isolated from the breast cancer tissues and adjacent or prophylactic normal breast tissues from four BRCA1 mutation carriers and three noncarriers. Whole-exome sequencing was performed on breast tumors from the four BRCA1 mutation carriers; for validation, bulk RNA-seq was performed on adjacent normal breast tissues from eight additional BRCA1 mutation carriers and 14 noncarriers. Correlation analyses suggested that breast cancers in BRCA1 mutation carriers might originate from luminal cells. The aberrant luminal progenitor cells with impaired differentiation were significantly increased in normal breast tissues in BRCA1 mutation carriers compared with noncarriers. These observations were further validated by the bulk RNA-seq data from additional BRCA1 mutation carriers. These data suggest that the cell of origin of basal-like breast tumors (ERneg) in BRCA1 mutation carriers might be luminal progenitor cells. The expression of TP53 and BRCA1 was decreased in luminal progenitor cells from normal breast tissue in BRCA1 mutation carriers, which might trigger the basal/mesenchymal transition of luminal progenitors and might result in basal-like tumor development. Furthermore, ERhigh luminal tumors might originate from mature luminal cells. Our study provides in-depth evidence regarding the cells of origin of different breast cancer subtypes in BRCA1 mutation carriers. SIGNIFICANCE: Single-cell RNA-seq data indicate that basal-like breast cancer (ERneg) might originate from luminal progenitors, and ERhigh luminal breast cancer might originate from mature luminal cells in BRCA1 mutation carriers. ©2021 American Association for Cancer Research.

Entities:  

Year:  2021        PMID: 33727227     DOI: 10.1158/0008-5472.CAN-20-2123

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  A human breast atlas integrating single-cell proteomics and transcriptomics.

Authors:  G Kenneth Gray; Carman Man-Chung Li; Jennifer M Rosenbluth; Laura M Selfors; Nomeda Girnius; Jia-Ren Lin; Ron C J Schackmann; Walter L Goh; Kaitlin Moore; Hana K Shapiro; Shaolin Mei; Kurt D'Andrea; Katherine L Nathanson; Peter K Sorger; Sandro Santagata; Aviv Regev; Judy E Garber; Deborah A Dillon; Joan S Brugge
Journal:  Dev Cell       Date:  2022-05-25       Impact factor: 13.417

2.  Liquid Biopsy Landscape in Patients with Primary Upper Tract Urothelial Carcinoma.

Authors:  Stephanie N Shishido; Alireza Ghoreifi; Salmaan Sayeed; George Courcoubetis; Amy Huang; Brandon Ye; Sankalp Mrutyunjaya; Inderbir S Gill; Peter Kuhn; Jeremy Mason; Hooman Djaladat
Journal:  Cancers (Basel)       Date:  2022-06-18       Impact factor: 6.575

3.  Newly identified breast luminal progenitor and gestational stem cell populations likely give rise to HER2-overexpressing and basal-like breast cancers.

Authors:  James R W McMullen; Ubaldo Soto
Journal:  Discov Oncol       Date:  2022-05-28

4.  Dissecting the heterogeneity and tumorigenesis of BRCA1 deficient mammary tumors via single cell RNA sequencing.

Authors:  Heng Sun; Jianming Zeng; Zhengqiang Miao; Kuan Cheok Lei; Chen Huang; Lingling Hu; Sek Man Su; Un In Chan; Kai Miao; Xu Zhang; Aiping Zhang; Sen Guo; Si Chen; Ya Meng; Min Deng; Wenhui Hao; Haipeng Lei; Ying Lin; Zhonglin Yang; Dongjiang Tang; Koon Ho Wong; Xiaohua Douglas Zhang; Xiaoling Xu; Chu-Xia Deng
Journal:  Theranostics       Date:  2021-10-25       Impact factor: 11.556

5.  Single-cell and spatially resolved analysis uncovers cell heterogeneity of breast cancer.

Authors:  Si-Qing Liu; Zhi-Jie Gao; Juan Wu; Hong-Mei Zheng; Bei Li; Si Sun; Xiang-Yu Meng; Qi Wu
Journal:  J Hematol Oncol       Date:  2022-03-03       Impact factor: 17.388

6.  Modification of BRCA1-associated breast cancer risk by HMMR overexpression.

Authors:  Francesca Mateo; Zhengcheng He; Lin Mei; Gorka Ruiz de Garibay; Carmen Herranz; Nadia García; Amanda Lorentzian; Alexandra Baiges; Eline Blommaert; Antonio Gómez; Oriol Mirallas; Anna Garrido-Utrilla; Luis Palomero; Roderic Espín; Ana I Extremera; M Teresa Soler-Monsó; Anna Petit; Rong Li; Joan Brunet; Ke Chen; Susanna Tan; Connie J Eaves; Curtis McCloskey; Razq Hakem; Rama Khokha; Philipp F Lange; Conxi Lázaro; Christopher A Maxwell; Miquel Angel Pujana
Journal:  Nat Commun       Date:  2022-04-07       Impact factor: 14.919

7.  Evidence for accelerated aging in mammary epithelia of women carrying germline BRCA1 or BRCA2 mutations.

Authors:  Sundus F Shalabi; Masaru Miyano; Rosalyn W Sayaman; Jennifer C Lopez; Tiina A Jokela; Michael E Todhunter; Stefan Hinz; James C Garbe; Martha R Stampfer; Kai Kessenbrock; Victoria E Seewaldt; Mark A LaBarge
Journal:  Nat Aging       Date:  2021-09-14

8.  Pathogenic BRCA1 variants disrupt PLK1-regulation of mitotic spindle orientation.

Authors:  Zhengcheng He; Ryan Ghorayeb; Susanna Tan; Ke Chen; Amanda C Lorentzian; Jack Bottyan; Syed Mohammed Musheer Aalam; Miguel Angel Pujana; Philipp F Lange; Nagarajan Kannan; Connie J Eaves; Christopher A Maxwell
Journal:  Nat Commun       Date:  2022-04-22       Impact factor: 17.694

9.  Role of Ultrasound Imaging in the Prediction of TRIM67 in Brain Metastases From Breast Cancer.

Authors:  Zhidong Xuan; Ting Ma; Yue Qin; Yajie Guo
Journal:  Front Neurol       Date:  2022-06-20       Impact factor: 4.086

Review 10.  Impact of Immune Cell Heterogeneity on HER2+ Breast Cancer Prognosis and Response to Therapy.

Authors:  Milena Perrone; Giovanna Talarico; Claudia Chiodoni; Sabina Sangaletti
Journal:  Cancers (Basel)       Date:  2021-12-17       Impact factor: 6.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.